| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
IC50: 81.0 nM (MCT1)[1] GI50: 20 μM (A-549); 15.1 μM (MCF-7)[1]
The primary targets of MCT1-IN-3 are MCT1 (monocarboxylate transporter 1, also known as SLC16A1) and ABCB1 (P-glycoprotein, multidrug transporter). MCT1 is a transmembrane transporter that mediates the uptake of monocarboxylates such as lactate and pyruvate, which are important for cellular metabolism. ABCB1 is a multidrug efflux pump that contributes to drug resistance in cancer cells. MCT1-IN-3 inhibits MCT1 with an IC50 of 81.0 nM and also inhibits ABCB1. |
|---|---|
| ln Vitro |
With an IC50 value of 81.0 nM, MCT1-IN-3 (compound 24) exhibits inhibitory effect against MCT1[1]. With GI50 values of 20 μM and 15.1 μM, respectively, MCT1-IN-3 has potent anti-proliferative action against MCT1-expressing cancer cell lines A-549 and MCF-7[1]< /sup>. MCT1-IN-3 (5 μM; 24 h) induces apoptosis and cell cycle arrest in cancer [1]. It has been demonstrated that MCT1-IN-3 (1.0, 2.0, 3.5, and 5.0 μM) sensitizes these cancer cells to anti-tumor medications [1]. It has been demonstrated that MCT1-IN-3 reverses ABCB1-mediated multidrug resistance (MDR) and has a strong inhibitory effect on the multidrug transporter ABCB1 [1].
MCT1-IN-3 is a potent MCT1 inhibitor with an IC50 of 81.0 nM. It shows significant anti-proliferative activity against MCT1-expressing cancer cell lines A-549 and MCF-7, with GI50 values of 20 μM and 15.1 μM, respectively. At 5 μM for 24 hours, MCT1-IN-3 significantly induces cancer cell cycle arrest and apoptosis. The compound also exhibits significant inhibitory activity against ABCB1 and reverses ABCB1-mediated multidrug resistance. |
| ln Vivo |
In vivo, MCT1-IN-3 would be expected to exert antitumor effects by inhibiting MCT1-mediated metabolism and reversing ABCB1-mediated multidrug resistance. Its efficacy would be assessed in animal models of cancer, with endpoints including tumor growth inhibition, analysis of MCT1 and ABCB1 inhibition, and assessment of cell cycle arrest and apoptosis.
|
| Enzyme Assay |
In vitro enzyme activity assays for MCT1-IN-3 typically involve measuring its ability to inhibit MCT1-mediated transport. MCT1 transport assays are performed using cells expressing MCT1. Cells are incubated with radiolabeled lactate or pyruvate in the presence of increasing concentrations of MCT1-IN-3, and the inhibition of transport is measured. The reported IC50 is 81.0 nM. ABCB1 inhibition is assessed using efflux assays with fluorescent ABCB1 substrates.
|
| Cell Assay |
Cell Cycle Analysis[1]
Cell Types: A-549 cells Tested Concentrations: 5 μM Incubation Duration: 24 h Experimental Results: Caused a disruption of the cell cycle of A-549 cancer cells, indicated by a shift from the predominant Go/G, phase . Apoptosis Analysis[1] Cell Types: A-549 cells Tested Concentrations: 5 μM Incubation Duration: 24 h Experimental Results: Increased the percentage of total apoptotic cells by a factor of 13 from 0.51 to 6.68%. Cellular assays for MCT1-IN-3 involve treating MCT1-expressing cancer cell lines (A-549 and MCF-7) with the compound and measuring its effects on cell proliferation, cell cycle progression, and apoptosis. Readouts include cell viability (GI50 values of 20 μM and 15.1 μM for A-549 and MCF-7, respectively), cell cycle analysis (G1/S arrest), and apoptosis markers. ABCB1-mediated multidrug resistance reversal is assessed using drug accumulation and cytotoxicity assays. |
| Animal Protocol |
In vivo efficacy of MCT1-IN-3 would be evaluated in mouse xenograft models of cancer. The compound could be administered orally or via injection. Efficacy endpoints would include tumor growth inhibition, analysis of MCT1 and ABCB1 inhibition in tumor tissue, and assessment of cell cycle arrest and apoptosis.
|
| ADME/Pharmacokinetics |
MCT1-IN-3 has a molecular weight of 389.40 and a molecular formula of C22H19N3O4. It is a potent MCT1 inhibitor with an IC50 of 81.0 nM. The compound also inhibits ABCB1 and reverses multidrug resistance. It shows anti-proliferative activity against A-549 and MCF-7 cells with GI50 values of 20 μM and 15.1 μM, respectively. It is supplied with a purity of 99.35%. The compound is for research use only and is not intended for human therapeutic use.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for MCT1-IN-3 in the provided literature. As a research compound, its safety profile would be an important consideration for in vivo applications. Potential toxicities could be related to its effects on MCT1-mediated metabolism and ABCB1 function in normal tissues. Standard preclinical safety studies would be required to evaluate its safety for potential therapeutic applications. The compound is for research use only and is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
MCT1-IN-3 is a potent inhibitor of monocarboxylate transporter 1 (MCT1) with an IC50 of 81.0 nM. It also inhibits ABCB1 and reverses multidrug resistance. MCT1-IN-3 shows significant anti-proliferative activity against MCT1-expressing cancer cell lines A-549 and MCF-7, with GI50 values of 20 μM and 15.1 μM, respectively. At 5 μM for 24 hours, it induces cancer cell cycle arrest and apoptosis. MCT1-IN-3 has a molecular formula of C22H19N3O4 and a molecular weight of 389.40.
|
| Molecular Formula |
C22H19N3O4
|
|---|---|
| Molecular Weight |
389.403965234756
|
| Exact Mass |
389.137
|
| CAS # |
2878360-80-4
|
| PubChem CID |
166642635
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
29
|
| Complexity |
675
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)NC(=O)CN2C=C(C3=CC=CC=C32)/C=C(\C#N)/C(=O)OC
|
| InChi Key |
RAJPEVIHJCKTGX-RVDMUPIBSA-N
|
| InChi Code |
InChI=1S/C22H19N3O4/c1-28-18-9-7-17(8-10-18)24-21(26)14-25-13-16(11-15(12-23)22(27)29-2)19-5-3-4-6-20(19)25/h3-11,13H,14H2,1-2H3,(H,24,26)/b15-11+
|
| Chemical Name |
methyl (E)-2-cyano-3-[1-[2-(4-methoxyanilino)-2-oxoethyl]indol-3-yl]prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5681 mL | 12.8403 mL | 25.6805 mL | |
| 5 mM | 0.5136 mL | 2.5681 mL | 5.1361 mL | |
| 10 mM | 0.2568 mL | 1.2840 mL | 2.5681 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
